A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6832-6842

  Kaeppler, Ulrich ^a   Stiefl, Nikolaus ^a   Schiller, Markus ^a   Vicik, Radim ^a   Breuning, Alexander ^a   Schmitz, Werner ^b   Rupprecht, Daniel ^a   Schmuck, Carsten ^a   Baumann, Knut ^a   Ziebuhr, John ^a   Schirmeister, Tanja ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 [2,3 DICHLORO 4 (2 METHYLENEBUTYRYL)PHENOXY]ACETYLAMINO] 2 METHYLPROPIONIC ACID CARBOXAMIDE; CORONAVIRUS MAIN PROTEASE MPRO; CORONAVIRUS MAIN PROTEASE MPRO INHIBITOR; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; ETACRYNIC ACID TERT BUTYLAMIDE; PHENYL GROUP; UNCLASSIFIED DRUG;

ARTICLE; COVALENT BOND; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME SUBSTRATE COMPLEX; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; NONHUMAN; SARS CORONAVIRUS;

EID: 27444440007     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0501782     Document Type: Article

References (63)

1. Siddell, S. G.; Ziebuhr, J.; Snijder, E. J. Coronaviruses, toroviruses, and arteriviruses. In Topley and Wilson's Microbiology and Microbial Infections, 10th ed.; Mahy, B. W. J., ter Meulen, V., Eds.; Virology, Vol. 1.; Hodder Arnold: London, 2005; pp 823-856.
2. Enjuanes, L.; van der Zeijst, B. A. M. Molecular basis of transmissible gastroenteritis virus epidemiology. In The Coronaviridae; Siddell, S. G., Ed.; Plenum Press: New York, 1995; pp 337-376.
3. Drosten, C.; Günther, S.; Preiser, W.; van der Werf, S.; Brodt, H. R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A.; Berger, A.; Burguiere, A. M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J. C.; Muller, S.; Rickerts, V.; Sturmer, M.; Vieth, S.; Klenk, H. D.; Osterhaus, A. D.; Schmitz, H.; Doerr, H. W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1967-1976.
4. Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P. E.; Dowell, S. F.; Ling, A. E.; Humphrey, C. D.; Shieh, W. J.; Guarner, J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J. Y.; Cox, N.; Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1953-1966.
5. Peiris, J. S.; Lai, S. T.; Poon, L. L.; Guan, Y.; Yam, L. Y.; Lim, W.; Nicholls, J.; Yee, W. K.; Yan, W. W.; Cheung, M. T.; Cheng, V. C.; Chan, K. H.; Tsang, D. N.; Yung, R. W.; Ng, T. K.; Yuen, K. Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319-1325.
6. Guan, Y.; Zheng, B. J.; He, Y. Q.; Liu, X. L.; Zhuang, Z. X.; Cheung, C. L.; Luo, S. W.; Li, P. H.; Zhang, L. J.; Guan, Y. J.; Butt, K. M.; Wong, K. L.; Chan, K. W.; Lim, W.; Shortridge, K. F.; Yuen, K. Y.; Peiris, Y. S.; Poon, L. L. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302, 276-278.
7. Peiris, J. S.; Yuen, K. Y.; Osterhaus, K. D.; Stohr, K. The severe acute respiratory syndrome. N. Engl. J. Med. 2003, 349, 2431-2441.
8. Ziebuhr, J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr. Opin. Microbiol. 2004, 7, 412-419.
9. Ziebuhr, J. The coronavirus replicase. Curr. Top. Microbiol. Immunol. 2005, 287, 57-94.
10. Ziebuhr, J.; Snijder, E. J.; Gorbalenya, A. E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 2000, 81, 853-879.
11. Anand, K.; Palm, G. J.; Mesters, J. R.; Siddell, S. G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002, 21, 3213-3224.
12. Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
13. Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; Gao, G. F.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190-13195.
14. Liu, B.; Zhou, J. SARS-CoV protease inhibitors design using virtual screening method from natural products libraries. J. Comput. Chem. 2005, 26, 484-490.
15. Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiranam, N. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs. Biochem. Biophys. Res. Commun. 2004, 321, 370-378.
16. Chou, K.-C.; Wei, D.-Q.; Zhong, W.-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. 2003, 308, 148-151.
17. Jenwitheesuk, E.; Samudrala, R. Identifying inhibitors of the SARS coronavirus proteinase. Bioorg. Med. Chem. Lett. 2003, 13, 3989-3992.
18. Zhang, X. W.; Yap, Y. L.; Altmeyer, R. M. Generation of predictive pharmacophore model for SARS-coronavirus main proteinase. Eur. J. Med. Chem. 2005, 40, 57-62.
19. Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K.-C. Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase. Anal. Biochem. 2005, 337, 262-270.
20. Xiong, B.; Gui, C.-S.; Xu, X.-Y.; Luo, C.; Chen, J.; Luo, H.-B.; Chen, L.-L.; Li, G.-W.; Sun, T.; Yu, C.-Y.; Yue, L.-D.; Duan, W.-H.; Shen, J.-K.; Qin, L.; Li, Y.-X.; Chen, K.-X.; Luo, X.-M.; Shen, X.; Shen, J.-H.; Jiang, H.-L. A 3D model of SARS-CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharm. Sin. 2003, 24, 497-504.
21. Zhang, X.-W.; Yap, Y. L. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIC, psychotic and parasitic drugs. Bioorg. Med. Chem. 2004, 12, 2517-2521.
22. Toney, J. H.; Navas-Martin, S.; Weiss, S. R.; Koeller, A. Sabadinine: A potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. J. Med. Chem. 2004, 47, 1079-1080.
23. Wu, C. Y.; Jan, J. T.; Ma, S. H.; Kuo, C. J.; Juan, H. F.; Cheng, Y. S.; Hsu, H. H.; Huang, H. C.; Wu, D.; Brik, A.; Liang, F. S.; Liu, R. S.; Fang, J. M.; Chen, S. T.; Liang, P. H.; Wong, C. H. Small molecule targeting severe acute respiratory syndrome human coronavirus. Proc. Nat. Acad. Sci. U.S.A. 2004, 101, 10012-10017.
24. Blanchard, J. E.; Elowe, N. H.; Huitema, C.; Fortin, P. D.; Cechetto, J. D.; Eltis, L. D.; Brown, E. D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 2004, 11, 1445-1453.
25. Kao, R. Y.; To, A. P. C.; Ng, L. W. Y.; Tsui, W. H. W.; Lee, T. S. W.; Tsoi, H.-W.; Yuen, K.-Y. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. FEBS Lett. 2004, 576, 325-330.
26. Hsu, J. T.-A.; Kuo, J.-C.; Hsieh, H.-P.; Wang, Y.-C.; Huang, K.-K.; Lin, C. P.-C.; Huang, P.-F.; Chen, X.; Liang, P.-H. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett. 2004, 574, 116-120.
27. pro. Biochemistry 2004, 43, 4906-4912.
28. Matthews, D. A.; Dragovich, P. S.; Webber, S. E.; Fuhrman, S. A.; Patick, A. K.; Zalman, S. L.; Hendrickson, T. F.; Love, R. A.; Prins, T. J.; Marakovits, J. T.; Zhou, R.; Tikhe, J.; Ford, C. E.; Meador, J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Brothers, M. A.; DeLisle, D. M.; Worland, S. T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11000-11007.
29. 17
30. Schirmeister, T.; Klockow, A. Cysteine protease inhibitors containing small rings. Mini-Rev. Med. Chem. 2003, 3, 585-596.
31. Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 2002, 102, 4639-4750.
32. Ro, S.; Baek, S. G.; Lee, B.; Ok, J. H. Conformational studies of irreversible HIV-1 protease inhibitors containing cis-epoxide as an amide isostere. J. Pept. Res. 1999, 54, 242-248.
33. Sprague, J. M. Diuretics. Top. Med. Chem. 1986, 2, 1-63.
34. Kaeppler, U.; Schirmeister, T. New nonpeptidic inhibitors of papain derived from etacrynic acid. Med. Chem. 2005, 1, 361-370.
35. Martina, E.; Stiefl, N.; Degel, B.; Schulz, F.; Breuning, A.; Schiller, M.; Vicik, R.; Baumann, K.; Ziebuhr, J.; Schirmeister, T. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS CoV main protease inhibitor. Bioorg. Med. Chem. Lett. 2005, in press.
36. Ziebuhr, J.; Heusipp, G.; Siddell, S. G. Biosynthesis, purification, and characterization of the human 229E 3C-like proteinase. J. Virol. 1997, 71, 3992-3997.
37. Hegyi, A.; Ziebuhr, J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 2002, 83, 595-599.
38. pro cleavage site). The lower enzyme activity against this substrate is reflected in the higher incubation time used in the HPLC-based assays.
39. FlexX, version 1.12; BioSolveIT (An der Ziegelei 75, 53757): St. Augustin, Germany, 2003.
40. In some of the docking poses the studied compounds were not located within the binding site but were docked to the surface of the protein. Consequently, the "best" docking pose in this study was defined as the pose with the most favorable docking score for compounds that were located inside the binding pocket. For all virtual compounds (i.e., those that were not readily synthesized when the docking study was carried out) a further constraint was added. Since the activated double bond of compound 6a was predicted to be in proximity to the active site Cys145 and since it was the working hypothesis that this double bond reacts with Cys145, only those docking poses were scrutinized where the double bond was close to Cys145.
41. His163 N-H ↔ O=C: 1.76 Å, angle NHO 153.1. Glu166 C=O ↔ H-N: 1.97 Å, angle NHO 169.3. Gln189 N-H ↔ O=C: 1.94 Å, angle NHO 141.1.
42. Adding the van der Waals radii of the involved heavy atoms sulfur and carbon results in 3.4 Å. Hence, when only noncovalent interactions are modeled, the two atoms cannot move closer because clashes are penalized by the scoring function of the docking tool.
43. Glu166 C=O ↔ H-N: 1.66 Å, angle NHO 159.5. Gln189 N-H ↔ O=C: 2.03 Å, angle NHO 170.2.
44. Thr190 C=O ↔ H-N: 1.70 Å, angle NHO 147.6. Gln192 N-H ↔ O=C: 2.03 Å, angle NHO 147.0.
45. Wang, Q. M.; Johnson, R. B.; Sommergruber, W.; Shepherd, T. A. Development of in vitro peptide substrates for human rhinovirus-12 2A protease. Arch. Biochem. Biophys. 1998, 356, 12-18.
46. The descriptors ortho and meta are used with respect to the phenolic hydroxyl group.
47. Rang, H. P.; Dale, M. M.; Ritter, J. M.; Moore, P. K. Pharmacology, 5th ed.; Churchill Livingstone: Edinburgh, U.K., 2003; p 362.
48. Hasannejad, H.; Takeda, M.; Taki, K.; Shin, H. J.; Babu, E.; Jutabha, P.; Khamdang, S.; Aleboyeh, M.; Onozato, M. L.; Tojo, A.; Enomoto, A.; Anzai, N.; Narikawa, S.; Huang, X.-L.; Niwa, T.; Endou, H. Interactions of human organic anion transporters with diuretics. J. Pharmacol. Exp. Ther. 2004, 308, 1021-1029.
49. Thiel, V.; Ivanov, K. A.; Putics, A.; Hertzig, T.; Schelle, B.; Bayer, S.; Weissbrich, B.; Snijder, E. J.; Rabenau, H.; Doerr, H. W.; Gorbalenya, A: E.; Ziebuhr, J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 2003, 84, 2305-2315.
50. Liu, Y: Y.; Kati, W.; Chen, C. M.; Tripathi, R.; Molla, A.; Kohlbrenner, W. Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction. Anal. Biochem. 1999, 267, 331-335.
51. i values could be determined. Dialysis assays with the CAC1 cysteine protease cathepsin B showed the inhibitors to act reversibly (unpublished results).
52. GraFit; Erithacus Software Ltd.: London, 1994.
53. Diago-Meseguer, J.; Palomo-Coll, A. L.; Fernandez-Lizarbe, J. R.; Zugaza-Bilbao, A. A new reagent for activating carboxyl groups: preparation and reactions of N,N-bis[2-oxo-3-oxazolidinyl]phosphorodiamidic chloride. Synthesis 1980, 547-551.
54. Robertson, A. Experiments on the synthesis of rotenone and its derivatives. Part II. The synthesis of rissic acid and of derric acid, and the constitution of rotenone, deguelin, and tephrosin. J. Chem. Soc., Abstr. 1932, 1380-1388.
55. Coulthard, C. E.; Marshall, J.; Payman, F. L. The variation of phenol coefficients in homologous series of phenols. J. Chem. Soc., Abstr. 1930, 280-291.
56. Buu-Hoi, N P.; Xuong, N. D.; Lavit, D. Halogenated o- and p-phenolic ketones. J. Chem. Soc. 1954, 1034-1038.
57. Nguyen, H.; Buu, H. Ketones derived from o-halogenated anisoles and phenetoles. C. R. Hebd. Seances Acad. Sci. 1947, 224, 1363.
58. Pinchuk, A. M.; Kosinskaya, I. M.; Shevchenko, V. I. N-(Cyanoalkyl)-and N-(cyanocycloalkyl)phosphorimidic trichlorides. Zh. Obshch. Khim. 1967, 37, 856-859.
59. Ziegler, E.; Schredt, H.; Gitschthaler, K. Synthesis of benzofulvenes. Monatsh. Chem. 1954, 85, 1234-1239.
60. Feniak, G.; Reckhow, W. A. Procede de photographie en couleurs et nouveaux produits pour sa mise en oeuvre (Procedure for color photography and new products for its implementation). Patent BE 560859, 1957 (Eastman Kodak Co.).
61. Pawar, R. A.; Shingte, R. D.; Gogte, V. N. Synthesis of potential plant growth regulators. Synthesis of 2-N-alkyl-5-chlorophenoxyacetic acids. Indian J. Chem. 1970, 8, 522-525.
62. SYBYL, version 6.9; Tripos Inc. (1699 South Hanley Road, St. Louis, MO 63144), 2001.
63. Yang, H.; Xie, W.; Xue, X.; Yang, K.; Ma, J.; Liang, W.; Zhao, Q.; Zhou, Z.; Pei, D.; Ziebuhr, J.; Hilgenfeld, R.; Yuen, K. Y.; Wong, L.; Gao, G.; Chen, S.; Chen, Z.; Ma, D.; Bartlam, M.; Rao, Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLOS Biol. 2005, 3, (10).